Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WS-CART-CS1 in Multiple Myeloma
NCT06185751Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2024
- Primary completion
- Aug 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of WS-CART-CS1 in multiple myeloma (MM) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Treatment-Emergent Adverse Events at 24 months and Dose-Limiting Toxicities at 28 days. Started Aug 2024; status: recruiting.
02
Drugs
WS-CART-CS1
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06185751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06185751.